-
公开(公告)号：US10941181B2
公开(公告)日：2021-03-09
申请号：US15226161
申请日：2016-08-02
Applicant: immatics biotechnologies GmbH
Inventor： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC: A61K38/00 , C07K7/06 , A61K39/00 , C07K7/08 , A61K35/17 , G01N33/574 , C07K14/74 , A61M5/00 , C12N5/0783
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US10709735B2
公开(公告)日：2020-07-14
申请号：US16507437
申请日：2019-07-10
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC: A61K35/17 , A61K39/00 , C07K14/47 , C07K14/495 , C07K14/725 , C07K19/00 , C12N5/0783 , C07K7/06 , C07K7/08 , C07K16/40 , C12N9/02 , C12N9/10 , A61K38/00
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US10420800B2
公开(公告)日：2019-09-24
申请号：US16196402
申请日：2018-11-20
Applicant: Immatics Biotechnologies GmbH
Inventor： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC: A61K35/17 , C07K14/47 , C07K14/495 , C12N9/02 , A61K39/00 , C07K7/06 , C07K7/08 , C07K19/00 , C07K14/725 , C07K16/40 , C12N5/0783 , C12N9/10 , A61K38/00
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US10046037B2
公开(公告)日：2018-08-14
申请号：US15226081
申请日：2016-08-02
Applicant: immatics biotechnologies GmbH
Inventor： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC: A61K35/17 , A61K39/00 , C07K7/06 , C07K7/08 , G01N33/574 , C07K14/74 , A61M5/00 , C12N5/0783 , A61K38/00
CPC classification number: C07K7/06 , A61K35/17 , A61K38/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/572 , A61K2039/605 , A61K2039/6081 , A61K2039/6093 , A61M5/002 , C07K7/08 , C07K14/70539 , C07K2319/00 , C07K2319/40 , C12N5/0638 , C12N2501/50 , G01N33/57492 , Y02A50/472
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US09993540B2
公开(公告)日：2018-06-12
申请号：US15638806
申请日：2017-06-30
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
CPC classification number: C07K7/06 , A61K35/17 , A61K38/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/572 , A61K2039/605 , A61K2039/6081 , A61K2039/6093 , A61M5/002 , C07K7/08 , C07K14/70539 , C07K2319/00 , C07K2319/40 , C12N5/0638 , C12N2501/50 , G01N33/57492 , Y02A50/472
Abstract: A method of treating a patient who has brain cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has brain cancer. A method of treating a patient who has brain cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the brain cancer.
-
Patent Agency Ranking
公开(公告)号：US20170326217A1
公开(公告)日：2017-11-16
申请号：US15638806
申请日：2017-06-30
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC: A61K39/00
CPC classification number: C07K7/06 , A61K35/17 , A61K38/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/572 , A61K2039/605 , A61K2039/6081 , A61K2039/6093 , A61M5/002 , C07K7/08 , C07K14/70539 , C07K2319/00 , C07K2319/40 , C12N5/0638 , C12N2501/50 , G01N33/57492 , Y02A50/472
Abstract: A method of treating a patient who has brain cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has brain cancer. A method of treating a patient who has brain cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the brain cancer.
-
公开(公告)号：US11986497B2
公开(公告)日：2024-05-21
申请号：US18166936
申请日：2023-02-09
Applicant: Immatics Biotechnologies GmbH
Inventor： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC: C07K7/06 , A61K35/17 , A61K39/00 , C07K7/08 , C07K14/47 , C07K14/495 , C07K14/725 , C07K16/40 , C07K19/00 , C12N5/0783 , C12N9/02 , C12N9/10 , A61K38/00
CPC classification number: A61K35/17 , A61K39/0011 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , A61K38/00 , A61K2039/5158 , A61K2039/572 , C07K2317/34 , C07K2319/00 , C12N2502/1157 , C12Y208/02011
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US11208434B2
公开(公告)日：2021-12-28
申请号：US17384152
申请日：2021-07-23
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC: A61K35/17 , C07K7/06 , C12N5/0783 , C07K14/74 , A61K39/00 , A61M5/00 , G01N33/574 , C07K7/08 , A61K38/00
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US10906936B2
公开(公告)日：2021-02-02
申请号：US15226098
申请日：2016-08-02
Applicant: immatics biotechnologies GmbH
Inventor： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC: A61K38/00 , C07K7/06 , A61K39/00 , C07K7/08 , A61K35/17 , G01N33/574 , C07K14/74 , A61M5/00 , C12N5/0783
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US10434120B2
公开(公告)日：2019-10-08
申请号：US16196440
申请日：2018-11-20
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
-
-
-
-
-
-
-
-
Search Results
25
records
(took 0.03 seconds)
